Full text is available at the source.
Abstract
Liraglutide's therapeutic application is significantly hindered by poor absorption and a short biological half-life.
- Glucagon-like peptide-1 (GLP-1) analogs mimic the natural incretin hormone, influencing glucose metabolism.
- These analogs stimulate insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.
- Liraglutide is recognized for its potential in treating type 2 diabetes, obesity, and cardiovascular disorders.
- Challenges in liraglutide's use include unintended off-target effects and limited bioavailability.
- Various nanocarrier-based systems have been explored to enhance liraglutide's delivery and therapeutic efficacy.
Simplified